China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data

China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data

Source: 
Fierce Pharma
snippet: 

In the global race to develop an effective vaccine to protect people against the novel coronavirus, China’s CanSino Bio has leapt ahead.

CanSino and its collaborators at the Academy of Military Medical Sciences’ Institute of Biotechnology plan to move their adenovirus type-5 vector-based recombinant COVID-19 vaccine, Ad5-nCoV, into phase 2 clinical trial in China “soon,” the company said in a disclosure (PDF) to the Hong Kong Stock Exchange on Thursday.